Kim Doh Hyun, Lee Eun Hee, Hwang Jae Chul, Jeung Jai Hak, Kim Do Hyun, Cheong Jae Youn, Cho Sung Won, Kim Young Bae
Department of Gastroenterology, Ajou University College of Medicine, Suwon, Korea.
Taehan Kan Hakhoe Chi. 2002 Sep;8(3):317-20.
Orlistat(Xenical(R), Roche) is considered a safe and effective drug to treat obesity by reduced absorption of 30% digested fat. To date, no serious adverse effects affecting the liver have been published except a case of subacute hepatic failure leading to liver transplantation in a young women with moderate obesity treated with orlistat. We report a case of acute cholestatic hepatitis in a young woman with moderate obesity treated with orlistat: a 33-year-old female admitted for the evaluation of jaundice. Abdominal ultrasonography, ERCP, routine chemistry, viral markers, and a fine needle biopsy of liver were performed. Microscopic findings of the liver biopsy specimen were compatible with acute cholestatic hepatitis. After steroid therapy, liver function was improved.
奥利司他（赛尼可，罗氏公司）被认为是一种安全有效的药物，可通过减少30%消化脂肪的吸收来治疗肥胖症。迄今为止，除了一名接受奥利司他治疗的中度肥胖年轻女性发生亚急性肝衰竭并接受肝移植的病例外，尚未有影响肝脏的严重不良反应的报道。我们报告一例接受奥利司他治疗的中度肥胖年轻女性发生急性胆汁淤积性肝炎的病例：一名33岁女性因黄疸入院评估。进行了腹部超声检查、内镜逆行胰胆管造影（ERCP）、常规生化检查、病毒标志物检测以及肝脏细针活检。肝活检标本的显微镜检查结果与急性胆汁淤积性肝炎相符。经过类固醇治疗后，肝功能得到改善。
